Lv33
270 积分 2025-03-04 加入
A novel oral prodrug (CK301) for effusive feline infectious peritonitis: An open-label study evaluating dose optimization and therapeutic efficacy
2小时前
已完结
Enhancing the Oral Bioavailability of a Poorly Soluble Pan-CK2 Kinase Inhibitor: Leveraging a Phosphate Prodrug Strategy to Overcome Dissolution-Limited Absorption and Improve Systemic Exposure during Dose Escalation
1天前
已完结
Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects
1天前
已完结
Discovery of KDX1381, a Bivalent CK2α Inhibitor for the Treatment of Solid Tumors as a Single Agent or in Combination
2天前
已完结
Discovery andCharacterization of RP04340 : A Highly Potent and OrallyActive Pan-KRAS PROTAC Degrader
7天前
已完结
Strategic Useof the Necessary Nitrogen Atom for HolisticProperty-Based Drug Design
9天前
已完结
Retrospective Analysis of the Impact of the “Escape from Flatland” Publication on the Merck & Co., Inc., Small Molecule Portfolio
15天前
已完结
CNS penetrant TEAD1,2,4 inhibitor MSC-4070 derived from phenotypic screening hit optimization
19天前
已完结
Structure-Based Design of Potent TLR7/8/9 Triple Antagonists: Overcoming High Tissue Distribution and Reactive Metabolite Liabilities
20天前
已完结
Application of Bioisosteres in the Design and Discovery of FDA-Approved Drugs and Advanced Clinical Candidates
21天前
已完结
皖公网安备34019202002308
